Selected research
Market Structure
Global Long-acting Reversible Contraceptives (LARCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Long-acting Reversible Contraceptives (LARCs) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Long-acting Reversible Contraceptives (LARCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Long-acting Reversible Contraceptives (LARCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Long-acting Reversible Contraceptives (LARCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Long-acting Reversible Contraceptives (LARCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Long-acting Reversible Contraceptives (LARCs) include AbbVie Allergan, ASPIVIX, Cooper Companies, Durbin, H & J Medical, HRA Pharma, Laboratoire 7 MED, Laboratoire CCD and OCON, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Long-acting Reversible Contraceptives (LARCs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Long-acting Reversible Contraceptives (LARCs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Long-acting Reversible Contraceptives (LARCs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Reversible Contraceptives (LARCs) market size, projected growth trends, production technologies, key applications, and end-use industries.
Long-acting Reversible Contraceptives (LARCs) Segment by Company
AbbVie Allergan
ASPIVIX
Cooper Companies
Durbin
H & J Medical
HRA Pharma
Laboratoire 7 MED
Laboratoire CCD
OCON
Pregna
Prosan
Shanghai Dahua Pharmaceuticals
Williams Medical Supplies
Yantai JiShengYaoXie
Bayer
Merck
Long-acting Reversible Contraceptives (LARCs) Segment by Type
Copper Intrauterine Devices
Hormonal Intrauterine Devices
Contraceptive Implants
Others
Long-acting Reversible Contraceptives (LARCs) Segment by Application
Age 20-24
Age 25-34
Age 35-44
Others
Long-acting Reversible Contraceptives (LARCs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Reversible Contraceptives (LARCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting Reversible Contraceptives (LARCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Reversible Contraceptives (LARCs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Long-acting Reversible Contraceptives (LARCs) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-acting Reversible Contraceptives (LARCs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-acting Reversible Contraceptives (LARCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Long-acting Reversible Contraceptives (LARCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Copper Intrauterine Devices
- Hormonal Intrauterine Devices
- Contraceptive Implants
- Others
Applications
- Age 20-24
- Age 25-34
- Age 35-44
- Others
Companies covered
- AbbVie Allergan
- ASPIVIX
- Cooper Companies
- Durbin
- H & J Medical
- HRA Pharma
- Laboratoire 7 MED
- Laboratoire CCD
- OCON
- Pregna
- Prosan
- Shanghai Dahua Pharmaceuticals
- Williams Medical Supplies
- Yantai JiShengYaoXie
- Bayer
- Merck
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Long-acting Reversible Contraceptives (LARCs) Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Long-acting Reversible Contraceptives (LARCs) Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Long-acting Reversible Contraceptives (LARCs) Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Long-acting Reversible Contraceptives (LARCs) Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Long-acting Reversible Contraceptives (LARCs) Market Dynamics
- 2.1 Long-acting Reversible Contraceptives (LARCs) Industry Trends
- 2.2 Long-acting Reversible Contraceptives (LARCs) Industry Drivers
- 2.3 Long-acting Reversible Contraceptives (LARCs) Industry Opportunities and Challenges
- 2.4 Long-acting Reversible Contraceptives (LARCs) Industry Restraints
3 Long-acting Reversible Contraceptives (LARCs) Market by Manufacturers
- 3.1 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Manufacturers (2021-2026)
- 3.2 Global Long-acting Reversible Contraceptives (LARCs) Sales by Manufacturers (2021-2026)
- 3.3 Global Long-acting Reversible Contraceptives (LARCs) Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Long-acting Reversible Contraceptives (LARCs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Long-acting Reversible Contraceptives (LARCs) Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Long-acting Reversible Contraceptives (LARCs) Manufacturers, Product Type & Application
- 3.7 Global Long-acting Reversible Contraceptives (LARCs) Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Long-acting Reversible Contraceptives (LARCs) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Long-acting Reversible Contraceptives (LARCs) Players Market Share by Revenue in 2025
- 3.8.3 2025 Long-acting Reversible Contraceptives (LARCs) Tier 1, Tier 2, and Tier 3
4 Long-acting Reversible Contraceptives (LARCs) Market by Type
- 4.1 Long-acting Reversible Contraceptives (LARCs) Type Introduction
- 4.1.1 Copper Intrauterine Devices
- 4.1.2 Hormonal Intrauterine Devices
- 4.1.3 Contraceptive Implants
- 4.1.4 Others
- 4.2 Global Long-acting Reversible Contraceptives (LARCs) Sales by Type
- 4.2.1 Global Long-acting Reversible Contraceptives (LARCs) Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Long-acting Reversible Contraceptives (LARCs) Sales by Type (2021-2032)
- 4.2.3 Global Long-acting Reversible Contraceptives (LARCs) Sales Market Share by Type (2021-2032)
- 4.3 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Type
- 4.3.1 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Type (2021-2032)
- 4.3.3 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Type (2021-2032)
5 Long-acting Reversible Contraceptives (LARCs) Market by Application
- 5.1 Long-acting Reversible Contraceptives (LARCs) Application Introduction
- 5.1.1 Age 20-24
- 5.1.2 Age 25-34
- 5.1.3 Age 35-44
- 5.1.4 Others
- 5.2 Global Long-acting Reversible Contraceptives (LARCs) Sales by Application
- 5.2.1 Global Long-acting Reversible Contraceptives (LARCs) Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Long-acting Reversible Contraceptives (LARCs) Sales by Application (2021-2032)
- 5.2.3 Global Long-acting Reversible Contraceptives (LARCs) Sales Market Share by Application (2021-2032)
- 5.3 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Application
- 5.3.1 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Application (2021-2032)
- 5.3.3 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Application (2021-2032)
6 Global Long-acting Reversible Contraceptives (LARCs) Sales by Region
- 6.1 Global Long-acting Reversible Contraceptives (LARCs) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Long-acting Reversible Contraceptives (LARCs) Sales by Region (2021-2032)
- 6.2.1 Global Long-acting Reversible Contraceptives (LARCs) Sales by Region (2021-2026)
- 6.2.2 Global Long-acting Reversible Contraceptives (LARCs) Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Long-acting Reversible Contraceptives (LARCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Long-acting Reversible Contraceptives (LARCs) Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Long-acting Reversible Contraceptives (LARCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Long-acting Reversible Contraceptives (LARCs) Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region
- 7.1 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region
- 7.1.1 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region (2021-2026)
- 7.1.3 Global Long-acting Reversible Contraceptives (LARCs) Revenue by Region (2027-2032)
- 7.1.4 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Long-acting Reversible Contraceptives (LARCs) Revenue (2021-2032)
- 7.2.2 North America Long-acting Reversible Contraceptives (LARCs) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Long-acting Reversible Contraceptives (LARCs) Revenue (2021-2032)
- 7.3.2 Europe Long-acting Reversible Contraceptives (LARCs) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Long-acting Reversible Contraceptives (LARCs) Revenue (2021-2032)
- 7.4.2 Asia-Pacific Long-acting Reversible Contraceptives (LARCs) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 AbbVie Allergan
- 8.1.1 AbbVie Allergan Company Information
- 8.1.2 AbbVie Allergan Business Overview
- 8.1.3 AbbVie Allergan Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 AbbVie Allergan Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.1.5 AbbVie Allergan Recent Developments
- 8.2 ASPIVIX
- 8.2.1 ASPIVIX Company Information
- 8.2.2 ASPIVIX Business Overview
- 8.2.3 ASPIVIX Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 ASPIVIX Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.2.5 ASPIVIX Recent Developments
- 8.3 Cooper Companies
- 8.3.1 Cooper Companies Company Information
- 8.3.2 Cooper Companies Business Overview
- 8.3.3 Cooper Companies Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Cooper Companies Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.3.5 Cooper Companies Recent Developments
- 8.4 Durbin
- 8.4.1 Durbin Company Information
- 8.4.2 Durbin Business Overview
- 8.4.3 Durbin Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Durbin Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.4.5 Durbin Recent Developments
- 8.5 H & J Medical
- 8.5.1 H & J Medical Company Information
- 8.5.2 H & J Medical Business Overview
- 8.5.3 H & J Medical Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 H & J Medical Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.5.5 H & J Medical Recent Developments
- 8.6 HRA Pharma
- 8.6.1 HRA Pharma Company Information
- 8.6.2 HRA Pharma Business Overview
- 8.6.3 HRA Pharma Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 HRA Pharma Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.6.5 HRA Pharma Recent Developments
- 8.7 Laboratoire 7 MED
- 8.7.1 Laboratoire 7 MED Company Information
- 8.7.2 Laboratoire 7 MED Business Overview
- 8.7.3 Laboratoire 7 MED Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Laboratoire 7 MED Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.7.5 Laboratoire 7 MED Recent Developments
- 8.8 Laboratoire CCD
- 8.8.1 Laboratoire CCD Company Information
- 8.8.2 Laboratoire CCD Business Overview
- 8.8.3 Laboratoire CCD Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Laboratoire CCD Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.8.5 Laboratoire CCD Recent Developments
- 8.9 OCON
- 8.9.1 OCON Company Information
- 8.9.2 OCON Business Overview
- 8.9.3 OCON Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 OCON Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.9.5 OCON Recent Developments
- 8.10 Pregna
- 8.10.1 Pregna Company Information
- 8.10.2 Pregna Business Overview
- 8.10.3 Pregna Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Pregna Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.10.5 Pregna Recent Developments
- 8.11 Prosan
- 8.11.1 Prosan Company Information
- 8.11.2 Prosan Business Overview
- 8.11.3 Prosan Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Prosan Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.11.5 Prosan Recent Developments
- 8.12 Shanghai Dahua Pharmaceuticals
- 8.12.1 Shanghai Dahua Pharmaceuticals Company Information
- 8.12.2 Shanghai Dahua Pharmaceuticals Business Overview
- 8.12.3 Shanghai Dahua Pharmaceuticals Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Shanghai Dahua Pharmaceuticals Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.12.5 Shanghai Dahua Pharmaceuticals Recent Developments
- 8.13 Williams Medical Supplies
- 8.13.1 Williams Medical Supplies Company Information
- 8.13.2 Williams Medical Supplies Business Overview
- 8.13.3 Williams Medical Supplies Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Williams Medical Supplies Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.13.5 Williams Medical Supplies Recent Developments
- 8.14 Yantai JiShengYaoXie
- 8.14.1 Yantai JiShengYaoXie Company Information
- 8.14.2 Yantai JiShengYaoXie Business Overview
- 8.14.3 Yantai JiShengYaoXie Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Yantai JiShengYaoXie Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.14.5 Yantai JiShengYaoXie Recent Developments
- 8.15 Bayer
- 8.15.1 Bayer Company Information
- 8.15.2 Bayer Business Overview
- 8.15.3 Bayer Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Bayer Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.15.5 Bayer Recent Developments
- 8.16 Merck
- 8.16.1 Merck Company Information
- 8.16.2 Merck Business Overview
- 8.16.3 Merck Long-acting Reversible Contraceptives (LARCs) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Merck Long-acting Reversible Contraceptives (LARCs) Product Portfolio
- 8.16.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Long-acting Reversible Contraceptives (LARCs) Value Chain Analysis
- 9.1.1 Long-acting Reversible Contraceptives (LARCs) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Long-acting Reversible Contraceptives (LARCs) Production Mode & Process
- 9.2 Long-acting Reversible Contraceptives (LARCs) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Long-acting Reversible Contraceptives (LARCs) Distributors
- 9.2.3 Long-acting Reversible Contraceptives (LARCs) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst